Consent Decree On Ranbaxy Expands U.S. FDA Oversight To India
This article was originally published in PharmAsia News
Ranbaxy set to lose 180-day exclusivity on three products, potentially five more as it begins process to meet new requirements.
You may also be interested in...
FDA will lift a portion of its import alert for generic drugs made in two of Ranbaxy's facilities to allow the company to import antiviral ganciclovir to avoid a drug shortage
Companies are racing to co-develop coronavirus treatments before finalizing deal teams. These team-ups raise questions about what happens after the pandemic subsides.
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.